Document is current
Any future updates will be listed below
-
Authors
Goldney, Jonathan
Hamza, Malak
Surti, Farhaana
Davies, Melanie J.
Papamargaritis, Dimitris
-
Funding
Funding for this research was provided by:
Wellcome Trust Leicestershire Healthcare Inequalities Improvement Doctoral Training Programme (223512/Z/21/Z)
NIHR Leicester Biomedical Research Centre
- License Information
-
More Information
Article History
Accepted: 13 July 2025
First Online: 28 July 2025
Declarations
:
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: Professor Melanie Davies has acted as a consultant/advisor and speaker for Eli Lilly, Novo Nordisk and Sanofi, has attended advisory boards for Abbvie, Amgen, AstraZeneca, Biomea Fusion, Carmot/Roche, Sanofi, Zealand Pharma Regeneron, GSK and EktaH and as a speaker for AstraZeneca and Boehringer Ingelheim. She has received grants from AstraZeneca, Boehringer Ingelheim and Novo Nordisk. Dimitris Papamargaritis has acted as a speaker for Novo Nordisk, Eli Lilly and Boehringer Ingelheim and Johnson and Johnson and has received grants from Novo Nordisk, Novo Nordisk UK Research Foundation, Academy of Medical Sciences/Diabetes UK, Health Education East Midlands and the NIHR.
